Jazz Pharmaceuticals plc
JAZZ
$167.10
$0.390.23%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.13B | 1.05B | 897.84M | 1.09B | 1.05B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.13B | 1.05B | 897.84M | 1.09B | 1.05B |
| Cost of Revenue | 128.88M | 116.27M | 74.74M | 90.92M | 111.61M |
| Gross Profit | 997.23M | 929.44M | 823.10M | 997.25M | 943.36M |
| SG&A Expenses | 379.15M | 358.40M | 514.01M | 399.73M | 325.77M |
| Depreciation & Amortization | 168.37M | 162.10M | 154.45M | 158.90M | 157.46M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 874.60M | 826.74M | 923.85M | 859.61M | 794.76M |
| Operating Income | 251.51M | 218.97M | -26.01M | 228.56M | 260.21M |
| Income Before Tax | 8.99M | -735.64M | -110.35M | 133.20M | 200.52M |
| Income Tax Expenses | -242.42M | -17.17M | -17.81M | -57.91M | -14.53M |
| Earnings from Continuing Operations | 251.41M | -718.47M | -92.54M | 191.12M | 215.06M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 251.41M | -718.47M | -92.54M | 191.12M | 215.06M |
| EBIT | 251.51M | 218.97M | -26.01M | 228.56M | 260.21M |
| EBITDA | 429.76M | 392.98M | 138.86M | 396.98M | 425.44M |
| EPS Basic | 4.14 | -11.74 | -1.52 | 3.16 | 3.50 |
| Normalized Basic EPS | 2.09 | 1.73 | -0.82 | 1.77 | 2.04 |
| EPS Diluted | 4.08 | -11.74 | -1.52 | 3.11 | 3.42 |
| Normalized Diluted EPS | 2.06 | 1.73 | -0.82 | 1.74 | 1.98 |
| Average Basic Shares Outstanding | 60.70M | 61.19M | 60.98M | 60.54M | 61.41M |
| Average Diluted Shares Outstanding | 61.61M | 61.19M | 60.98M | 61.50M | 63.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |